Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Transfusion|July 8, 2022
Analysis of stem cell collections in adult patients with Ewing sarcomaGeorg-Nikolaus Franke, Roald Pfannes, Simone Heyn, et al.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|March 2, 2026
Associations between CT Radiomics Analyses and Hematopoietic Cell Mobilization in Patients with Multiple Myeloma: An Exploratory AnalysisJakob Leonhardi, Tihomir Dermendzhiev, Enrica Bach, et al.
Frontiers in Oncology|October 4, 2021
Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two CasesKristin Gerhardt, Madlen Jentzsch, Thomas Georgi, et al.
Frontiers in Oncology|January 24, 2022
Case Report: Large Granular Lymphocyte Leukemia (LGLL)-A Case Series of Challenging PresentationsNatali Pflug, Annika Littauer, David Beverungen, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2024
Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple MyelomaJanine Kirchberg, Luise Fischer, Patrick Born, et al.
Transfusion|October 18, 2023
Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myelomaRaphael Teipel, Susanne Rieprecht, Karolin Trautmann-Grill, et al.
Hemasphere|June 16, 2025
Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myelomaPatrick Born, David Fandrei, Song Yau Wang, et al.
Transfusion|July 29, 2025
Impact of cellular composition and T-cell senescence of mononuclear cell concentrates on the manufacturing process of chimeric antigen receptor (CAR) T-cellsVladan Vučinić, Theresa Tumewu, Mandy Brückner, et al.
Blood Cancer Discovery|October 23, 2024
Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple MyelomaDavid Fandrei, Sabine Seiffert, Michael Rade, et al.
Leukemia|January 6, 2024
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myelomaLuise Fischer, Nora Grieb, Patrick Born, et al.
Pageof 3